These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2564819)

  • 1. Somatostatin analogues in diabetes mellitus.
    Davies RR; Turner SJ; Alberti KG; Johnston DG
    Diabet Med; 1989 Mar; 6(2):103-11. PubMed ID: 2564819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
    Plewe G; Nölken G; Krause U; del Pozo E; Beyer J
    Scand J Gastroenterol Suppl; 1986; 119():166-9. PubMed ID: 2876502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
    Wurzburger MI; Prelevic GM; Sonksen PH; Balint-Peric LA
    Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
    Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
    Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.
    Davies RR; Miller M; Turner SJ; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG
    Clin Endocrinol (Oxf); 1986 Dec; 25(6):739-47. PubMed ID: 2888547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice.
    Grønbaek H; Nielsen B; Schrijvers B; Vogel I; Rasch R; Flyvbjerg A
    J Endocrinol; 2002 Mar; 172(3):637-43. PubMed ID: 11874712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
    Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
    Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
    Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
    Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
    Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
    Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
    Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.